MX2020010821A - Anticuerpos contra galectina-10. - Google Patents

Anticuerpos contra galectina-10.

Info

Publication number
MX2020010821A
MX2020010821A MX2020010821A MX2020010821A MX2020010821A MX 2020010821 A MX2020010821 A MX 2020010821A MX 2020010821 A MX2020010821 A MX 2020010821A MX 2020010821 A MX2020010821 A MX 2020010821A MX 2020010821 A MX2020010821 A MX 2020010821A
Authority
MX
Mexico
Prior art keywords
galectin
antibodies
antagonists
clcs
charcot
Prior art date
Application number
MX2020010821A
Other languages
English (en)
Inventor
Christophe Blanchetot
Haard Hans De
Bart Lambrecht
Savvas Savvides
Hamida Hammad
Kenneth Verstraete
Jean-Michel Percier
Michael Saunders
Der Woning Bas Van
Emma Persson
Original Assignee
Argenx Iip Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1806099.6A external-priority patent/GB201806099D0/en
Priority claimed from GBGB1901648.4A external-priority patent/GB201901648D0/en
Application filed by Argenx Iip Bv filed Critical Argenx Iip Bv
Publication of MX2020010821A publication Critical patent/MX2020010821A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4724—Lectins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a antagonistas, particularmente anticuerpos y fragmentos de unión a antígeno de los mismos, que se unen a la proteína galectina-10, particularmente galectina-10 humana. Los antagonistas de galectina-10 interrumpen la cristalización de galectina-10 y, por lo tanto, son útiles en métodos para prevenir y tratar enfermedades y afecciones en donde la patología está vinculada a la formación/presencia de cristales de Charcot-Leyden (CLC).
MX2020010821A 2018-04-13 2019-04-12 Anticuerpos contra galectina-10. MX2020010821A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1806099.6A GB201806099D0 (en) 2018-04-13 2018-04-13 Galectin-10 Antibodies
GBGB1901648.4A GB201901648D0 (en) 2019-02-06 2019-02-06 Galectin-10 antibodies
PCT/EP2019/059570 WO2019197675A1 (en) 2018-04-13 2019-04-12 Galectin-10 antibodies

Publications (1)

Publication Number Publication Date
MX2020010821A true MX2020010821A (es) 2021-01-15

Family

ID=66240109

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020010821A MX2020010821A (es) 2018-04-13 2019-04-12 Anticuerpos contra galectina-10.

Country Status (12)

Country Link
US (3) US11066473B2 (es)
EP (1) EP3774905A1 (es)
JP (1) JP2021520825A (es)
KR (1) KR20210005070A (es)
CN (1) CN112166126A (es)
AU (1) AU2019250689A1 (es)
BR (1) BR112020020868A2 (es)
CA (1) CA3094215A1 (es)
IL (1) IL278010A (es)
MX (1) MX2020010821A (es)
SG (1) SG11202009140SA (es)
WO (1) WO2019197675A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020010821A (es) 2018-04-13 2021-01-15 Argenx Iip Bv Anticuerpos contra galectina-10.
US11860114B2 (en) * 2020-03-26 2024-01-02 David Hurwitz Determining atomic coordinates from X-ray diffraction data
US20230192865A1 (en) * 2020-05-06 2023-06-22 Cropedit Biotechnology Inc. Nano antibody and use thereof
CN113667000B (zh) * 2021-08-31 2022-08-19 中国医学科学院基础医学研究所 多肽在制备治疗2型免疫疾病的药物中的应用
CN113666999B (zh) * 2021-08-31 2022-08-19 中国医学科学院基础医学研究所 用于治疗2型免疫疾病的多肽
CN113999287B (zh) * 2021-12-02 2023-06-27 深圳湾实验室坪山生物医药研发转化中心 一种靶向半乳糖凝集素-10的多肽抑制剂及其制备方法和用途
CN118434440A (zh) 2022-01-18 2024-08-02 阿根思有限公司 Fab片段的雾化
AU2023208882A1 (en) 2022-01-18 2024-05-09 argenx BV Galectin-10 antibodies
WO2023150260A2 (en) * 2022-02-03 2023-08-10 Regents Of The University Of Minnesota Compounds that target tem8, compositions, and methods
WO2023153496A1 (ja) * 2022-02-10 2023-08-17 国立大学法人大阪大学 好酸球増多症又は気管支喘息バイオマーカー
CN115785245A (zh) * 2022-07-18 2023-03-14 上海博满生物科技有限公司 一种半乳糖凝集素10晶体及其制备的抗体IgY和药物制剂
CN115902204A (zh) * 2022-09-23 2023-04-04 北京大学第三医院（北京大学第三临床医学院） 一种外泌体形式半乳糖凝集素9的检测方法与试剂盒

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
DE10333406A1 (de) * 2003-07-15 2005-02-10 Protagen Ag T-regulatorische-Zellen enthaltend Galectine zur Therapie und Diagnose von Erkrankungen
GB2461546B (en) 2008-07-02 2010-07-07 Argen X Bv Antigen binding polypeptides
US11421016B2 (en) * 2015-04-23 2022-08-23 Nantomics Llc Cancer neoepitopes
CN106645752B (zh) * 2016-12-27 2018-02-16 中南大学湘雅医院 Galectin‑10及其特异性抗体在制备检测鼻咽癌试剂盒中的应用
MX2020010821A (es) 2018-04-13 2021-01-15 Argenx Iip Bv Anticuerpos contra galectina-10.

Also Published As

Publication number Publication date
AU2019250689A1 (en) 2020-10-08
KR20210005070A (ko) 2021-01-13
US20240026010A1 (en) 2024-01-25
US11713354B2 (en) 2023-08-01
US20190367619A1 (en) 2019-12-05
BR112020020868A2 (pt) 2021-04-06
CA3094215A1 (en) 2019-10-17
EP3774905A1 (en) 2021-02-17
US20210332140A1 (en) 2021-10-28
CN112166126A (zh) 2021-01-01
WO2019197675A1 (en) 2019-10-17
US11066473B2 (en) 2021-07-20
SG11202009140SA (en) 2020-10-29
IL278010A (en) 2020-11-30
JP2021520825A (ja) 2021-08-26

Similar Documents

Publication Publication Date Title
MX2020010821A (es) Anticuerpos contra galectina-10.
ZA202211057B (en) Anti-trem2 antibodies and methods of use thereof
EA201792221A1 (ru) Антитела против сортилина и способы их применения
EA202092825A1 (ru) Анти-sirpa антитела и способы их применения
EA201890039A1 (ru) Антитела, специфичные к гиперфосфорилированному тау-белку, и способы их применения
EA201890145A1 (ru) Антитела к фактору xi и способы их применения
EA201891732A1 (ru) Биспецифичные связывающие белки для pd-l1 и kdr
PH12019502463A1 (en) Anti-cd33 antibodies and methods of use thereof
EA201790342A1 (ru) Антитела к trem2 и способы их применения
MX360497B (es) Anticuerpos de proteina accesoria del receptor de interleucina-1 antihumana (il1 rap) y usos de los mismos.
MX2017001599A (es) Anticuerpos novedosos y sus usos.
EA201492149A1 (ru) St2-антигенсвязывающие белки
MX2023007840A (es) Anticuerpos anti-properdina monovalentes y fragmentos de anticuerpo.
EA201890447A1 (ru) Гуманизированные антитела к рецептору ccr7
EA202190138A1 (ru) Анти-sirp-бета1 антитела и способы их использования
MX2021006362A (es) Anticuerpos de dominio simple contra cll-1.
PH12017502020A1 (en) Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor
PH12021550332A1 (en) Anti-cd33 antibodies and methods of use thereof
EA201992460A1 (ru) Антитела-агонисты btla и их применение
EA202190183A1 (ru) Антитела к siglec-5 и способы их применения
MX2019009498A (es) Anticuerpos mimeticos de fgf21 y usos de los mismos.
EA202190647A1 (ru) Антитела к klrg1
PH12019501530A1 (en) AQUEOUS PHARMACEUTICAL COMPOSITION OF A RECOMBINANT MONOCLONAL ANTIBODY TO TNFa
MX2016011177A (es) Anticuerpos a la metaloproteinasa de matriz 9 y metodos de uso de los mismos.
MX2024006275A (es) Anticuerpos para galectina-10.